Hennion & Walsh Asset Management Inc. Makes New $564,000 Investment in CVS Health Corporation $CVS

Hennion & Walsh Asset Management Inc. purchased a new position in shares of CVS Health Corporation (NYSE:CVS) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,484 shares of the pharmacy operator’s stock, valued at approximately $564,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. SOA Wealth Advisors LLC. boosted its stake in shares of CVS Health by 36.9% during the third quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator’s stock valued at $37,000 after purchasing an additional 131 shares in the last quarter. Symmetry Partners LLC raised its holdings in CVS Health by 2.5% in the 3rd quarter. Symmetry Partners LLC now owns 5,826 shares of the pharmacy operator’s stock valued at $439,000 after buying an additional 141 shares during the last quarter. Harbor Capital Advisors Inc. grew its holdings in CVS Health by 72.1% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock worth $26,000 after acquiring an additional 142 shares during the last quarter. HF Advisory Group LLC increased its position in CVS Health by 2.9% in the 3rd quarter. HF Advisory Group LLC now owns 5,219 shares of the pharmacy operator’s stock valued at $393,000 after acquiring an additional 145 shares during the period. Finally, FineMark National Bank & Trust raised its stake in shares of CVS Health by 1.7% during the second quarter. FineMark National Bank & Trust now owns 9,576 shares of the pharmacy operator’s stock valued at $661,000 after acquiring an additional 157 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

CVS Health Stock Down 0.4%

CVS Health stock opened at $80.29 on Friday. The company has a market capitalization of $101.92 billion, a PE ratio of 211.29, a PEG ratio of 0.74 and a beta of 0.48. CVS Health Corporation has a 12-month low of $46.34 and a 12-month high of $85.15. The firm’s fifty day moving average is $78.70 and its 200 day moving average is $73.88. The company has a quick ratio of 0.63, a current ratio of 0.83 and a debt-to-equity ratio of 0.83.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.36 by $0.24. The firm had revenue of $102.87 billion during the quarter, compared to the consensus estimate of $98.85 billion. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The business’s revenue was up 7.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.09 earnings per share. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. As a group, sell-side analysts predict that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Thursday, January 22nd will be given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date of this dividend is Thursday, January 22nd. CVS Health’s dividend payout ratio is presently 700.00%.

Analysts Set New Price Targets

A number of research firms recently weighed in on CVS. Royal Bank Of Canada restated an “outperform” rating on shares of CVS Health in a report on Thursday, December 4th. Evercore ISI raised their price objective on CVS Health from $85.00 to $95.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. Wolfe Research increased their target price on shares of CVS Health from $85.00 to $100.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. JPMorgan Chase & Co. boosted their price target on shares of CVS Health from $93.00 to $101.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Finally, Wells Fargo & Company decreased their price objective on shares of CVS Health from $103.00 to $102.00 and set an “overweight” rating for the company in a research report on Thursday, November 13th. Two analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $94.86.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.